Updates are available Correction dated 2015-01-08

Click to view Correction: https://doi.org/10.1007/s11102-014-0628-z

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Crossref DOI link: https://doi.org/10.1007/s11102-014-0585-6

Published Online: 2014-08-08

Published Print: 2015-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark